



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/517,209	10/517,209 12/08/2004		Eberhard Ammermann	5000-0108PUS1	4348
2292	7590	09/20/2005		EXAMINER	
		KOLASCH &	QAZI, SABIHA NAIM		
PO BOX 74 FALLS CH	•	/A 22040-0747	ART UNIT	PAPER NUMBER	
	,		1616		

DATE MAILED: 09/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

$\mathcal{W}$							
	Application No.	Applicant(s)					
	10/517,209	AMMERMANN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Sabiha Qazi	1616					
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the o	correspondence address					
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D.  Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be ting will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).					
Status							
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This 3) ☐ Since this application is in condition for allowa	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.					
Disposition of Claims							
4) Claim(s) 1-9 is/are pending in the application.  4a) Of the above claim(s) is/are withdray  5) Claim(s) 1,2,5 and 6 is/are allowed.  6) Claim(s) 3, and 7 to 9 is/are rejected.  7) Claim(s) 4 is/are objected to.  8) Claim(s) are subject to restriction and/o							
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receiv u (PCT Rule 17.2(a)).	ion No ed in this National Stage					
Attachment(s)  1) Notice of References Cited (PTO-892)	4) 🔀 Interview Summary	ı (PTO-413)					
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	Paper No(s)/Mail D						

U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05)

Office Action Summary

### **Non-Final Office Action**

Claims 1-9 are pending. Claims 1, 2, 5 and 6 are allowed. Claim 4 is objected because it depends on a rejected claim. Claims 3, and 7-9 are rejected.

Closest prior art references are:

- 1. GB 857,388 teach dithia-anthracene compounds and their composition as fungicides,
- 2. US Patent 6,369,093 teach pyrazolecarboxamide as fungicides, it does not teach pyridine carboxamides as presently claimed.

None of them teach synergistically effective mixture of fungicides of formula I and II as presently claimed.

# Information Disclosure Statement

- 1. The information disclosure statement filed on 12/08/2004 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document.
- 2. The references BA—DE-1060655-B, BD-EP-0545 099 and BG-JP-2001/302 606 (no translation or English abstract) were not provided by the Applicants and therefore were not considered.

## Claim Rejections - 35 USC § 101

#### 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 9 provides for the use of the compounds of the formulae II, and I but, since the claim does not set forth any steps involved in the method/process, it is unclear what

Art Unit: 1616

method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claim 9 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

## Claim Rejections - 35 USC § 112

- 1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 2. Claims 3, and 7-8 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Following reasons apply:
- 3. In claim 3 "as biphenylamide II" is confusing, it may be deleted.

  Claims 7 and 8 are improperly dependent on two claims 1 and 6.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sabiha Qazi whose telephone number is (571) 272-0622. The examiner can normally be reached on any business day.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (571) 272-0887. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/517,209

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Thursday, September 15, 2005

SABIHA QAZI, PH.D PRIMARY EXAMINER

5.03/

Page 4